Alto’s midphase depression trial falls flat, raising doubts about pitch to disrupt neuropsychiatry R&D

Alto Neuroscience hit a bum note in an early test of its precision neuropsychiatry model. A phase 2b trial of Alto’s lead drug candidate in depression missed its primary and key secondary endpoints, prompting investors to wipe 60% off the biotech’s share price.